ibritumomab 1
consolidation 2
cycles 1
chop 2
plus 1
radiotherapy 1
highrisk 1
limitedstage 1
aggressive 2
bcell 2
lymphoma 5
swog 4
s 2
rchop 1
iodine 1
tositumomab 1
advanced 1
stage 1
diffuse 1
large 1
dlbcl 1
comparative 1
analysis 2
prognostic 1
factor 1
models 1
follicular 1
based 1
phase 2
iii 1
trial 2
choprituximab 1
versus 1
iodinetositumomab 1
ii 1
multicenter 1
hypercvad 1
mtxarac 1
rituximab 1
patients 2
previously 1
untreated 1
mantle 1
cell 1
natural 1
history 1
cns 1
relapse 1
nonhodgkins 1
followup 1
southwest 1
oncology 1
group 1
